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Abstract
Thyroid eye disease (TED) is a complex autoimmune disorder that may lead to
fundamental morbidity. TED presents with wide range of manifestations originating
radically from orbital inflammation which leading to exophthalmos, vision impairment,

Keywords

double vision, severe eye dryness and in advance cases vision loss may occur. On top of

•

Thyroid eye disease

that, it has also series of negative impacts on the patient quality of life, psychological and

•

Insulin-like

emotional well-being. The full clinical picture of thyroid eye disease (TED) can be

growth

factor receptor
•

Graves' disease

•

Thyroid-stimulating
hormone receptor

explained by the enlargement of the orbit. Corticosteroids are the gold stone of treatment
in TED. However, in case of steroids withdrawal recurrence is common. Moreover, in
the majority of the patients, the anatomy of the orbit is not replaced to the normal state,

•

Orbital fibroblast

that’s why rehabilitative surgery may be necessary to correct the deformity, diplopia and

•

Thyroid-stimulating

to maintain vision. Available treatment options for moderate-to-severe TED include

immunoglobulin

immunotherapy. The pathophysiology of TED has been reported to identify new

•

Glycosaminoglycan

effective therapeutic agents. Immunotherapies are on the top of the list as they have
shown considerable benefit affecting the nature course of the disease and improve the
quality of life of the patients. Options include Teprotumumab (anti-IGFR) that show
efficacy in improving exophthalmos, Rituximab (anti-CD20) decrease the inflammation
and Tocilizumab (anti-IL-6) with the capacity to benefit both of these manifestations.
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connective tissues, also parts of the skin. One

INTRODUCTION
Thyroid eye disease (TED) is an

manifestation of Graves’disease is thyroid-

autoimmune condition with many ophthalmic

associated ophthalmopathy, or thyroid eye

manifestations and psychosocial consequences.

disease, which is characterized by orbital

TED has been characterized to have an active

inflammation, tissue remodeling and fibrosis.

inflammatory phase which followed by disease

TED is most commonly associated with

inactivity. In TED, the muscles and fatty tissues

hyperthyroidism, however patients may be

of the orbit become edematous and inflamed,

hypothyroid or euthyroid[2,4].

pushing the eyeball forward and affecting the

Ophthalmic manifestations are reported

movements of the eye. Which lead to bulging

in around half of cases with GD, and patients

eyes (exophthalmos or proptosis)[1,2].

most commonly present in middle age and

Thyroid eye disease cases are mostly
related

to

an

overactive

gland

precede by endocrine manifestations. Symptoms

(hyperthyroidism state) and usually with one of

include puffiness of the eyes, lid retraction,

the most common causes of an overactive

proptosis, squint, conjunctival inflammation,

thyroid gland, which is

Graves' disease.

increased Intra ocular pressure, and rarely,

Symptoms of Graves’ disease include dry eye

vision may affected from keratitis or pressure on

and sometimes tearing, sense of eye irritation or

the optic nerve [2,4].

grittiness,

and

The stages of the disease divided to active and

redness, edema of the eyelids, photophobia and

latent. The active stage lasting for around 6

diplopia. Lately eye movement may be affected,

months up to 2 years. The term “active disease”

corneal ulceration, compression of the optic

stands for activation of the immune system [4,5].

conjunctival

thyroid

women are highly affected than men. TED may

inflammation

nerve and rarely, loss of vision[1,2,3].
Currently, treatment options included
many courses

of

steroid therapy, orbital

Effects of the active stage of grave’s disease
on the back and front of the eye.

radiotherapy and the recent way which is the

The muscles and fat tissue of the eye become

targeted

monoclonal

Rituximab
approved

and
by

antibodies

Teprotumumab,
the

US

Food

such

as

edematous, this swelling exerts a force on the

both

are

back of the eye causing it to protrude forward.

and

Drug

The changes of the back of the eye also include

Administration (FDA) for the medical treatment

thickening and scarring of connective tissue of

of TED[2,3].

the eye. However erythema, edema, proptosis

Clinical picture of TED

and lid retraction commonly noted in the front of

Graves’disease
syndrome

defined

involving

as

the
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Figure 1: Progressing (or “active”) Thyroid Eye Disease [5].
Effects of the Inactive stage of grave’s disease on the back and front of the eye.
Over the time in the inactive stage some changes, like swelling may improve and other changes like
protruding eyes, diplopia or strabismus may become permanent.

Figure 1: Inactive Stage Of Thyroid Eye Disease [5].

Other symptoms of Thyroid Eye Disease [6,7].

Drawn back eyelid, (lid retraction)

Foreign body sensation and dryness
Watery, teary eyes
Painful eyes










Color vision loss
Vision loss
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Eyelids are drawn back or retracted
This may lead to constant gaze
Difficulty in eye closure
Eyes feel dry
It feel like sand in the eyes
Extra fluid lead to blurred vision
Pain may be felt all around the eyes and
exaggerated in moving
Pressure around the eyes, result in
headaches
Colors look dull or washed out
In rare cases, all color vision may be lost
In advance cases, blindness may occur
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Table 1: Signs and symptoms of Thyroid Eye Disease [8].
Stage

Symptoms

Clinical Signs

Mild: Early-stage
TED

Gritty sensation; dry eye; excessive
watery eyes; chemosis or eyelid erythema
and swelling; unclear vision; retro-orbital
pain
Pulling sensation around the eye; eyelid
erythema and swelling; lid retraction and
protruding eyes

Mild, soft tissue inflammation; Focal dilations
of
the
conjunctival
vessels;
keratoconjunctivitis; corneal staining

advanced strabismus with diplopia;
progressing unclear vision; fading color
vision in one or both eyes; diminution in
visual acuity, visual field, and color vision
(signs of optic neuropathy)

Progressive exophthalmos
with eyelid
retraction, posterior blepharitis, keratitis and
inflammation of extraocular muscles and
fibrosis leading to strabismus and increased
IOP.

Moderate:
Progression
orbital
inflammation

of

Severe: Advanced
TED

edema of extraocular muscles; conjunctival
inflammation; eyelid swelling; exophthalmos;
extraocular muscles may be visible

Table 2: CAS, clinical activity score of Thyroid Eye Disease [9].

CAS
1
2
3
4
5
6
7
8
9
10

For initial assessment, only score items 1-7
Spontaneous orbital pain
Gaze evoked orbital pain
Eyelid swelling
Eyelid erythema
Conjunctival injection
Chemosis
Inflammation of caruncle or plica
Increase of >2mm in proptosis
Decrease in uniocular excursion in any way direction of > 8 degree
Decreased acuity equivalent to l Snellen line

Figure 2: An approximation of a curve depicting severity of thyroid eye disease over time that is based on a concept
by Rundle [9].
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The immune realization of both TSH-R

Pathophysiology of Thyroid Eye Disease
The Pathophysiology of active TED is described

and IGF-1R become evident to be merging with

by orbital tissues infiltration by immune cells

orbital tissue reactivity through recruitment of

(e.g., by T lymphocytes, mast cells and B

proinflammatory

lymphocytes). Orbital Fibroblasts groups can be

hyaluronan build up. Type 1 T helper (Th1)

further differentiate into myofibroblasts. Thus

cells,

lead to deposition of extracellular matrix and

macrophages infuse the orbit, and Th1 cells

hyaluronan in the orbital tissue. Expansion of

therefore produce cytokines such as [IL-

the

2].Inflammatory cytokines induce fibroblasts to

orbit

by

the

deposition

exaggerate

B

cytokine

lymphocytes,

release

mast

glycosaminoglycans,

cells

and

and

exophthalmos and affect eye motility. However

produce

the full detailed thyroid eye disease pathology

hyaluronan, that expand the intraorbital tissue

remain unclear, (TSH-R) intolerance and IGF-

through

1R; IGF-1R overexpression demonstrated to be

(Figure 3)[11,12].

adipose

and

muscle

including

enlargement

the main cause in the disease pathogenesis
[1,10].

Figure 3 A: Showes progression of the disease. An autoimmune process initiates an inflammatory response that
results in active phase TED. After the initial inflammation quiets, TED becomes inactive, Figure B and enters a
post-inflammatory, stable, fibrotic phase. Clinical picture include redness, pain, and edema. Histopathologic studies
show inflammatory cell infiltration during active TED with muscle fibers remaining intact or becoming fibrotic, and
a lack of inflammation as the disease progresses[8,11,12].
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Figure 4: Pathophysiology of thyroid eye disease (TED)[11].

The APCs incorporate TSHR and IGF-

Pathogenesis of Orbital Fibroblasts

1R then present them to helper T cells, in order

The main cell type involved in the

to this T cells are activated leading to 2 separate

pathophysiology of the TED and expanding of

ways either stimulating B cells to release auto-

orbital soft tissues appears to be the orbital

antibodies (GD-IgGs), or become auto-reactive

fibroblast (OF). OFs are found between muscle

T cells. GD-IgGs react with TSHR on thyroid

fibers in the interstitial space and inside orbital

follicular epithelial cells, causing follicular

fat. OFs strains divided depending on the

hyperplasia and hypertrophy. However, in

presence of Thy1 / CD90. In the extraocular

response to the chemo-attractants that released

muscles, Thy1-expressing (Thy1 +) OFs live.

by T cells, auto-reactive CD4 T cells take its

When

own pathway to the tissues of the orbit and react

differentiated into the contractile factor [14].

with

T cells

triggered,

myofibroblasts

can

be

and

Th1-deficient (Thy1-) OFs are orbit-

B cells and OrbitalFibroblasts release a wide ran

wide pre-adipocytes that can differentiate into

ge of inflammatory cytokines.IGF-1R

mature

and

adipocytes.

The

adipogenesis

and

TSHR forming a complex on the OFs surface

fibrosis cycles decide the relative proportion of

that reacts with GD-IgGs. OFs in TED derived

activated Thy1 + and Thy1− OFs. When OFs are

from bone marrow cells. Activated OFs can be

activated, hyaluronan build up and soft tissue

differentiated

enlargement leads to proliferation, [14].

into

either

adipocytes

or

myofibroblasts and hyaluronan synthesis has
been identified. This share in the expansion of
orbital soft tissues in TED [11,13].
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Figure 5: Orbital fibroblast stimulation induce pro-inflammatory genes, contributing to glycosaminoglycans
(GAGs) and hyaluronic acid synthesis. [14,15].

Pathogenesis of IGF-1R

bone marrow. In several cell types in TED,

Although, one of the auto-antigen in TED is the

including fibrocytes and orbital fibroblasts

IGF-1R.

waving

(OFs), IGF-1R is over-expressed and forms a

mechanism have many roles in development of

functional complex with TSHR, and its activity

the tissue and may be elaborate in basis of

is fundamental for mediating TSHR downstream

immunological disorders. IGF-I exerts immune

signaling components [13,16].

This

receptor

and

its

function regulatory activities and is expressed by
skilled immune cells and stromal cells of the

Figure 6: IGF-I exerts regulatory actions on immune function by stimulating B cells, T cells and neutrophils[13].

IGF-1 immuno-reactivity was demonstrated in

fibroblasts to synthesize GAGs and secrete

patients with TED on the surface of extraocular

chemoattractants,

muscle and orbital fat cells. Furthermore, the

inflammation and congestion. GAG deposition

rise in IGF-R1 expression in the tissue around

induces excessive fibrosis (scar tissue formation)

the eye plays a major role in the disease. When

in orbital tissues around the eye, this lead to

attached to the IGF-R1 receptors, antibodies

increase the pressure on nerves, blood vessels

against these receptors are released in patients

and eye tissue[13,15,16].

exaggerate

orbital

with TED.IGF-1-R activation induces orbital

Published by Mansoura Medical Journal, 2023
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Figure 7: IGF-1-R and TSH-R are activated by TSI (GD-IgG). Orbital cytokines are produced by the activation of
these receptors, leading to GAG deposition and orbital inflammation and congestion. [15].

Figure 8: Schematic diagram of the proposed model in which IGF-1R might participate in concert with TSHR in the
pathogenesis of GD[16].

Management of TED

to

severe

thyroid

eye

disease.

Recently many lines of treatment have

Glucocorticosteroids are the first-line agents

been updated to delay the progression of the

associated with high incidence of adverse effects

thyroid eye disease in a non-surgical way.

such as diabetes mellitus, hypertension, acute

Immunotherapy (mostly glucocorticosteroids),

heart disease, weight gain, osteoporosis and

orbital radiotherapy and decompression surgery

acute liver failure. However, the latest biological

are the latest choices that effective for moderate

therapy will alter the normal course of the

https://mmj.mans.edu.eg/home/vol51/iss1/2
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disease and reduce the occurrence of late
complications that might arise as a result of

Mechanism of action of Teprotumumab

inflammation fibrosis. [17,18].

It has been shown that insulin-like

Role of Teprotumumab in the management of

growth factor-1 receptors (IGF-1R) in case of

TED

TED are over-expressed by orbital fibroblasts, in

Teprotumumab is a fully human monoclonal

addition to being over-expressed in these

IgG1 antibody that targets human insulin-like

patients by T-cells and B-cells. Graves' disease

growth factor-1 receptor receptors. After a

IgG molecules have been found to mimic IGF-

clinical trial assessing its effectiveness in the

1R 's key ligand, insulin-like growth factor-1

treatment of thyroid eye disease (TED), it was

(IGF-1), and their IGF-1R binding induces the

approved by the FDA in January 2020 for the

expression of chemokines that play roles in

treatment of TED. Thyroid eye disease is a

tissue repair and inflammation. Teprotumumab

potentially

of

is an IgG1 monoclonal antibody which is

inflammation and tissue remodeling of Graves'

entirely human and directed against IGF-1R.It

disease behind the eye. Teprotumumab is the

binds to and allows these receptors to be

first pharmaceutical product to be licensed for

internalized and degraded, thereby preventing

TED treatment and is thus a major step forward

their

in the treatment of TED. In patients with

symptoms of thyroid eye disease. [22,23,24].

quiescent

crippling

TED,

complication

Teprotumumap

plays

downstream

effects

and

alleviating

an

important role in reducing proptosis and the
extraocular muscle size which altering the
course of disease[19,20,21].

Figure9: Left column: external preoperative and computed tomography of the orbit showing asymmetric left
exophthalmos before treatment. Right column: external photograph and computed tomography of the orbit showing
correction in exophthalmos and reduction in extraocular muscle size after three infusions of teprotumumab[23].
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Figure 10: pathogenic auto-antibodies stimulating the orbital fibroblast resulting in production of hyaluronan and
giving rise to symptoms of thyroid eye disease[23].
Figure 10: Teprotumumab (IGF-1R) blocks the stimulatory effects of the pathogenic auto-antibodies on the orbital
fibroblasts. TSI (thyroid stimulating immuno-globulins)[23].

Role of Rituximab in the management of

immunoglobulin (Ig) region of G1 [25,26].

TED
The

strategy

has

Its target is CD20 (differentiation

regulation

and

cluster), a surface marker of B cells that is

reduction of thyroid hormone production, not

present on pre-B and B cells, but generally not

immunosuppression,

of

on stem cells or plasma cells. Rituximab acts by

autoimmunity in the pathogenesis of GD.

depleting CD20 + cells via both antibody-and

However, biologic immunosuppressive therapy

supplement-mediated

has recently become a promising alternative for

apoptosis induction. It also has a direct impact

GD treatment with the use of rituximab.

on reducing inflammation and enhancing the

Rituximab is a monoclonal antibody of high

duration of the illness. [26,27,28].

concentrated

medical
on

care

of murine origin and a constant human

symptom

despite

the

role

pathways,

along with

affinity consisting of an antigen binding region

Figure11: Effect of the immunotherapy, Teprotumumap, Rituximab and tocilizumab on the TED[29].
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Role of Tocilizumab in the management of

clearer and better tailored treatments upgraded

TED

to affect the course of the disease.
Tocilizumab is an immunoglobulin G1

Immunotherapy, such as teprotumumab,

subclass recombinant humanised antihuman

rituximab and tocilizumab, are aimed at various

monoclonal

the

stages of the disease and significantly affects the

interleukin-6 receptor (IL-6R) developed by

pathology of the disease, enhances major disease

recombinant DNA technology. Tocilizumab

sequelae, including proptosis and diplopia, and

binds uniquely to both the soluble and

has demonstrated substantial changes in the

membrane-bound forms (IL-6RM) of IL-6R.IL-

quality of life of TED patients.

antibody

directed

against

6 is a proinflammatory cytokine formed by
different types of cells, including lymphocytes T

REFERENCES

and B, monocytes and fibroblasts. In the early
stages of TED, immune cells such as B and T
lymphocytes

play

a

major

role

in

the

pathophysiology [30,31].

[1] Douglas RS, Gupta S. The pathophysiology
of thyroid eye disease: implications for
immunotherapy.

However, high levels of IL-6 released
by differentiated adipocytes and fibroblasts

Current

opinion

in

ophthalmology. 2011 Sep 1;22(5):38590.

stimulate B lymphocytes and generate thyroid-

[2] Eslami, Fatemeh et al. “Prevalence of

stimulating immunoglobulin (TSI) in addition to

increased intraocular pressure in patients

an

with

immunomodulatory

development

of

role,

leading

to

glycosaminoglycan,

Graves'

ophthalmopathy

and

association with ophthalmic signs and

adipogenesis and inflammation or fibrosis.

symptoms

Reducing IL-6 's influence by blocking its

Iran.” Clinical ophthalmology (Auckland,

receptors can play a role in reducing blood

N.Z.) vol. 13 1353-1359. 25 Jul. 2019,

levels of TSI and improving proptosis and

doi:10.2147/OPTH.S205112

extraocular motility. [32,33,34].

into

disorder with many aggressive consequences
and impacts. TED's pathophysiology become

north-west

of

pathogenesis

and

thyroid-associated
Current

opinion

in

endocrinology, diabetes, and obesity.
2008 Oct;15(5):446.
[4]Stan, Marius N., and Rebecca S. Bahn.
"Risk

Published by Mansoura Medical Journal, 2023

the

management
ophthalmopathy.

TED is a progressive autoimmune

the

[3]Gianoukakis AG and Smith TJ. Recent
insights

Conclusion

in

factors

for

development

or

11

Mansoura Medical Journal, Vol. 51 [2023], Iss. 1, Art. 2

Shohieb et al.,

20

deterioration

of

ophthalmopathy." Thyroid 20.7

Graves'

Journal of Neuro-Ophthalmology. 2014

(2010):

Jun 1;34(2):177-85.

777-783.
[5]

Wu,

Lianqun,

et

al.

"Integrative

[12] Kumar, Seema, et al. "A stimulatory

transcriptomics and proteomic analysis

thyrotropin receptor antibody (M22) and

of extraocular muscles from patients with

thyrotropin

thyroid-associated

expression and secretion in Graves'

ophthalmopathy." Experimental

Eye

&

Research

preadipocyte

fibroblasts." Thyroid 20.1 (2010): 59-65.

[6] Dolman PJ. Evaluating graves’ orbitopathy.
Practice

interleukin-6

orbital

Research 193 (2020): 107962.

Best

increase

[13] Smith TJ and Janssen JA. Insulin-like

Clinical

growth factor-I receptor and thyroid-

Endocrinology & Metabolism. 2012 Jun

associated ophthalmopathy. Endocrine

1;26(3):229-48.

reviews. 2019 Feb;40(1):236-67.

[7] Salvi M. Immunotherapy for Graves’

[14] Turcu, Adina F., et al. "A small molecule

ophthalmopathy. Current Opinion in

antagonist inhibits thyrotropin receptor

Endocrinology, Diabetes and Obesity.

antibody-induced

2014 Oct 1;21(5):409-14.

functions involved in the pathogenesis of

[8] Patel A, Yang H and Douglas RS. A New

fibroblast

Graves ophthalmopathy." The Journal of

Era in the Treatment of Thyroid Eye

Clinical

Disease. Am

Metabolism 98.5 (2013): 2153-2159.

J

Ophthalmol.

2019;208:281-288.

Endocrinology

&

[15] Liaboe CA, Clark TJ, et al. Thyroid Eye

[9] Wang Y, Patel A and Douglas RS. Thyroid

Disease. 2016 Jun 1;34(2):177-85.

Eye Disease: How A Novel Therapy

[16] Smith TJ, Hegedüs L, Douglas RS. Role

May Change The Treatment Paradigm.

of insulin-like growth factor-1 (IGF-1)

Therapeutics

pathway in the pathogenesis of Graves’

and

Clinical

Risk

Management. 2019;15:1305.

orbitopathy. Best Practice & Research

[10] Novaes P, Grisolia AB, Smith TJ. Update

Clinical Endocrinology & Metabolism.

on thyroid-associated Ophthalmopathy
with a special emphasis on the ocular
surface.

Clinical

Diabetes

and

Endocrinology. 2016 Dec;2(1):1-0.
[11]

orbital

Shan

SJ,

Douglas

RS.

2012 Jun 1;26(3):291-302.
[17]

Azzam,

Shirin

"Tocilizumab

for

disease." Cochrane
The

pathophysiology of thyroid eye disease.

Hamed,

et

thyroid
Database

al.
eye
of

Systematic Reviews 11 (2018).
[18] Perez-Moreiras JV, Gomez-Reino JJ, et
al. Efficacy of Tocilizumab in Patients

https://mmj.mans.edu.eg/home/vol51/iss1/2
DOI: 10.21608/mjmu.2021.103779.1050

12

Shohieb et al.: Immunotherapy forthyroid eye disesase
21

Immunotherapy of thyroid Eye Disease

With Moderate-to-Severe CorticosteroidResistant

Graves

Orbitopathy:

A

physically scaffolds TSH and IGF1

Randomized Clinical Trial. American

receptors

Journal

2018

crosstalk." Endocrinology 160.6 (2019):

DOI:

1468-1479.

of

Ophthalmology.

Nov;195:181-190.
10.1016/j.ajo.2018.07.038.

to

enable

[25] Gürcan, Hakan M., et al. "A review

[19] Slentz, Dane H., Christine C. Nelson,

of the current use of rituximab in

and Terry J. Smith. "Teprotumumab: a

autoimmune

novel therapeutic monoclonal antibody

immunopharmacology 9.1 (2009).

for

thyroid-associated

ophthalmopathy." Expert
Investigational

Opinion

on

Drugs just-accepted

(2020).
[20]

[24] Krieger, Christine C., et al. "Arrestin-β-1

Douglas,

[26] Salvi, Mario, et al. "Efficacy of B-cell
targeted

S.,

et

al.

therapy

with rituximab

in

patients with active moderate to severe
Graves'

Raymond

diseases." International

orbitopathy:

controlled

a

study." The

randomized
Journal

of

"Teprotumumab for the treatment of

Clinical

active thyroid eye disease." New England

Metabolism 100.2 (2015): 422-431.

Journal of Medicine 382.4 (2020): 341-

[27] Savino, Gustavo, et al. "Intraorbital

352.

Endocrinology

&

injection of rituximab: a new approach

[21] Douglas R, Francis-Sedlak M, et al.
Teprotumumab

in

TED:

diplopia

outcome analysis. In American Society

for active thyroid-associated orbitopathy,
a

prospective

case

series." Minerva

endocrinologica 38.2 (2013): 173-179.

of Ophthalmic Plastic & Reconstructive

[28] Silkiss, Rona Z., et al. "Rituximab for

Surgery Annual Fall Meeting, Chicago

thyroid eye disease." Ophthalmic Plastic

2018 Oct 25.

& Reconstructive Surgery 26.5 (2010):

[22] Raychaudhuri N, Fernando R, et al.

310-314.

Thyrotropin regulates IL-6 expression in

[29] Hodgson NM and Rajaii F. Current

CD34+ fibrocytes: clear delineation of its

Understanding of the Progression and

cAMP-independent actions. PloS one.

Management

of

Thyroid

2013 Sep 25;8(9):e75100.

Orbitopathy:

A

Systematic

[23] Ozzello, Daniel J et al. “Early experience

Ophthalmology

with teprotumumab for chronic thyroid

Mar;9(1):21-33.

eye

disease.” American

ophthalmology

case

100744. 15 May. 2020.

Published by Mansoura Medical Journal, 2023

and

Associated
Review.

therapy.

2020

journal

of

[30] Perros P, Hegedus L, et al. Graves’

reports vol.

19

orbitopathy as a rare disease in Europe: a
European Group on Graves’ Orbitopathy

13

Mansoura Medical Journal, Vol. 51 [2023], Iss. 1, Art. 2

Shohieb et al.,

22

(EUGOGO) position statement. Orphanet
J Rare Dis. 2017;12:72.
[31] Maddaloni, Ernesto, and Raffaella
Buzzetti.

"Covid‐19

and

diabetes

mellitus: unveiling the interaction of two
pandemics." Diabetes/Metabolism
Research

and

Reviews (2020):

e33213321.
[32] Gross SM and Rotwein P. Unraveling
growth factor signaling and cell cycle
progression in individual fibroblasts.
Journal of Biological Chemistry. 2016
Jul 8;291(28):14628-38.
[33] Kooijman R, Coppens A. Insulin‐like
growth

factor‐I

stimulates

IL‐10

production in human T cells. Journal of
leukocyte biology. 2004 Oct;76(4):862-7.
[34]Vieira M, Gomes JR and Saraiva MJ.
Transthyretin induces insulin-like growth
factor I nuclear translocation regulating
its levels in the hippocampus. Molecular
neurobiology. 2015 Jun 1;51(3):1468-79.

https://mmj.mans.edu.eg/home/vol51/iss1/2
DOI: 10.21608/mjmu.2021.103779.1050

14

